ProCE Banner Activity

CE / CME

Strategies for Managing AEs and Promoting Adherence to CDK4/6 Inhibitors

Video

In this on-demand webcast, an expert discusses strategies for managing adverse events related to CDK4/6 inhibitor use in the treatment of early-stage and advanced breast cancers and promoting medication adherence.

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Released: February 11, 2025

Expiration: August 10, 2025

Share

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis Pharmaceuticals Corporation.

Lilly

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with HR+/HER2- breast cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Apply recommended strategies to improve patient recognition of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer and to monitor and manage the AEs appropriately

  • Initiate discussions with patients to identify and address challenges to adherence and persistence with oral therapies targeting CDK4/6

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Jamie L. Carroll, APRN, CNP, MSN

Assistant Professor of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Jamie L. Carroll, CNP, APRN, MSN: consultant/advisor/speaker: AstraZeneca, Lilly, Novartis.

Elizabeth Diaz, PA-C

Physician Assistant
Medical Oncology
UT Health San Antonio MD Anderson Cancer Center
San Antonio, Texas

Elizabeth Diaz, PA-C, has no relevant financial relationships to disclose.

Julia LaBarbera, MSN, RN, AGACNP-BC

Nurse Practitioner
UCLA Hematology Oncology
Santa Monica, California

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.

Nicolle Rochino, PharmD, RPh: employee (relationship has ended): Novo Nordisk.​

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 11, 2025, through August 10, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Physician Associate Continuing Medical Education 

AAPA CME Accreditation - AAPA

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until August 10, 2025. PAs should only claim credit commensurate with the extent of their participation. 

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.